Table of Content


Introduction
Cyclin Dependent Kise 4 (Cell Division Protein Kise 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Overview
Cyclin Dependent Kise 4 (Cell Division Protein Kise 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Therapeutics Development
Cyclin Dependent Kise 4 (Cell Division Protein Kise 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Therapeutics Assessment
Cyclin Dependent Kise 4 (Cell Division Protein Kise 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Companies Involved in Therapeutics Development
Cyclin Dependent Kise 4 (Cell Division Protein Kise 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Drug Profiles
Cyclin Dependent Kise 4 (Cell Division Protein Kise 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Dormant Products
Cyclin Dependent Kise 4 (Cell Division Protein Kise 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Discontinued Products
Cyclin Dependent Kise 4 (Cell Division Protein Kise 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Product Development Milestones
Appendix



List of Figures


Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Stage and Molecule Type, 2021


List of Tables


Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indications, 2021
Number of Products under Development by Indications, 2021 (Contd..1)
Number of Products under Development by Indications, 2021 (Contd..2)
Number of Products under Development by Indications, 2021 (Contd..3)
Number of Products under Development by Indications, 2021 (Contd..4)
Number of Products under Development by Companies, 2021
Number of Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021 (Contd..2)
Products under Development by Companies, 2021 (Contd..3)
Products under Development by Companies, 2021 (Contd..4)
Products under Development by Companies, 2021 (Contd..5)
Products under Development by Companies, 2021 (Contd..6)
Products under Development by Companies, 2021 (Contd..7)
Products under Development by Companies, 2021 (Contd..8)
Products under Development by Companies, 2021 (Contd..9)
Products under Development by Companies, 2021 (Contd..10)
Products under Development by Companies, 2021 (Contd..11)
Products under Development by Companies, 2021 (Contd..12)
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Aucentra Therapeutics Pty Ltd, 2021
Pipeline by Beta Pharma Inc, 2021
Pipeline by Betta Pharmaceuticals Co Ltd, 2021
Pipeline by CStone Pharmaceuticals Co Ltd, 2021
Pipeline by Eli Lilly and Co, 2021
Pipeline by ESSA Pharma Inc, 2021
Pipeline by Fochon Pharmaceutical Ltd, 2021
Pipeline by G1 Therapeutics Inc, 2021
Pipeline by Guangzhou BeBetter Medicine Technology Co Ltd, 2021
Pipeline by HEC Pharm Co Ltd, 2021
Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, 2021
Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2021
Pipeline by MEI Pharma Inc, 2021
Pipeline by Novartis AG, 2021
Pipeline by Nuvation Bio Inc, 2021
Pipeline by Onconova Therapeutics Inc, 2021
Pipeline by Pfizer Inc, 2021
Pipeline by Rizen (Suzhou) Biosciences Co Ltd, 2021
Pipeline by Sanofi, 2021
Pipeline by SATT Conectus Alsace SAS, 2021
Pipeline by Shanghai Haihe Biopharma Co Ltd, 2021
Pipeline by Shanghai Haishi Biopharmaceutical Co Ltd, 2021
Pipeline by Shanghai Junshi Bioscience Co Ltd, 2021
Pipeline by Shanghai Pharmaceutical Group Co Ltd, 2021
Pipeline by Shanghai Xunhe Pharmaceutical Technology Co Ltd, 2021
Pipeline by Shengke Pharmaceuticals (Jiangsu) Ltd, 2021
Pipeline by SignalRx Pharmaceuticals Inc, 2021
Pipeline by Sihuan Pharmaceutical Holdings Group Ltd, 2021
Pipeline by Sino Biopharmaceutical Ltd, 2021
Pipeline by Tetranov International Inc, 2021
Pipeline by Tiziana Life Sciences Plc, 2021
Pipeline by ViroStatics SRL, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Dormant Products, 2021 (Contd..2)
Discontinued Products, 2021